Solving The Silent Dropout Problem In Specialty Disease Trials: Why A PXO Is The Retention Engine Trials Desperately Need

In specialty disease trials, patient enrollment is only the starting line—retention determines success. Chronic conditions like multiple sclerosis, ulcerative colitis, lupus, and endometriosis demand high “decision investments” from patients, yet sponsors often lack systems to sustain engagement beyond recruitment. Traditional approaches treat dropouts as inevitable, but Jumo Health’s Patient Experience Optimization (PXO) model reframes retention as an operational design challenge, not a tracking metric.

PXO embeds behavioral science, health literacy, and human-centered design throughout the trial lifecycle, proactively addressing barriers that cause attrition. In specialty trials, where patient burdens are amplified by fluctuating symptoms and complex care pathways, PXO builds sustained engagement through tools like decision pathway mapping, comprehension reinforcement nudges, behavioral-triggered outreach, and post-trial transition kits. Results are measurable: PXO-powered specialty trials have achieved up to 42% reduction in dropouts, improved visit adherence, and enhanced patient comprehension and motivation metrics. PXO also alleviates pressures on sites.

For specialty trials, PXO isn’t an add-on—it’s an essential infrastructure that transforms retention from a costly vulnerability into a strategic advantage. Sponsors who design trials around the real patient experience see faster timelines, cleaner data, and deeper patient trust.